Background
==========

Type 2 diabetes mellitus (T2DM) is a major public health concern. It induces macro- and microvascular damage promoting long-term complications, like coronary heart disease (CHD), stroke or diabetic nephropathy, and is associated with significant morbidity and mortality \[[@B1],[@B2]\]. The risk of CHD and stroke is altered by age, gender, insulin and glycemic control in patients with diabetes mellitus \[[@B3]\], but gender-specific differences in the prevalence of cardiovascular diseases (CVD) might also decrease with rising age, especially in older women with diabetes compared to men of the same age \[[@B4]\].

Diabetes and CVD treatment is complex: besides the different applicable agents, disease status, comorbidities, self-management capabilities and individual compliance of patients have to be considered by the treating physicians \[[@B5],[@B6]\]. Diabetes treatment is generally intensified if CVD risk factors or comorbidities, such as hypertension, hypercholesterolemia or CHD, are present and vice versa \[[@B7],[@B8]\].

However, there is evidence that women tend to receive a less adequate therapeutic management than men \[[@B9],[@B10]\]. Until now, it is still unclear to what extent these gender differences can be explained by confounding factors, such as age, diabetes duration, adherence, prevalent depression or marital status \[[@B1],[@B11]\].

We aimed to analyze whether or not gender disparities exist in diabetes and CHD medication after controlling for the most important confounding factors in an outpatient population of diabetic patients in Germany.

Methods
=======

Study design and study population
---------------------------------

This analysis is based on data from the baseline examination of the DIANA study (Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice). DIANA is an epidemiological prospective cohort study with patients with T2DM conducted in the Ludwigsburg-Heilbronn area located in South-West Germany. The study was initiated in 2008 to address (short- and long-term) diabetes-related outcomes and to evaluate potentials for health care improvements in people with T2DM. People with a physician diagnosed T2DM aged 18 and older were recruited consecutively according to a standardized protocol by 38 general practitioners (GP) during regular practice visits between October 2008 and March 2010. The study protocol was approved by the Ethics Committees of the medical faculty of the University of Heidelberg and of the Chamber of Physicians of Baden-Württemberg.

Data collection
---------------

Participating patients completed a self-administered standardized questionnaire at baseline. Information related to diabetes and other medical conditions was reported by the attending physician through a standardized questionnaire. GPs reported all diabetes-relevant physician-diagnosed comorbidities ('yes'/ 'no') and submitted a complete list of all medications currently prescribed. Diabetes medication and CHD medication were classified according to the Anatomic Therapeutic Chemical (ATC) classification system (for more detailed information on classification see Additional file [1](#S1){ref-type="supplementary-material"}).

A blood sample was collected by the GP at time of recruitment and glycated haemoglobin A1c (HbA~1c~) was assessed by a central laboratory, using ion exchange high pressure liquid chromatography (HPLC) (G8, Tosoh Biosciences).

Definition of key variables
---------------------------

For the following variables information from the GP questionnaire was used and they were defined accordingly: body mass index (BMI) in kg/m², most recent high density lipoprotein level (HDL) in mg/dl and blood pressure (systolic/ diastolic) in mmHg, duration of diabetes and participation in a disease management program for T2DM (DMP-DM). CHD was defined as prevalent CHD or past myocardial infarction. Antidiabetic drugs were differentiated in biguanide, sulfonylurea, alpha-glucosidase inhibitor, thiazolidinedione, glinide, glucagon-like peptide-I (GLP-I) analogue exenatide, dipeptidyl peptidase-4 (DPP-4) inhibitor, oral combination drug (counted as one drug) and insulin treatment in general. Insulins were further specified in short acting human insulin, intermediate acting insulin (basal insulin), (human) insulin combination (short and intermediate acting) and insulin analogue. CHD medication was differentiated in antihypertensive drug, i.e. angiotensin-converting enzyme (ACE) inhibitor, diuretic, beta-blocker, calcium channel blocker and other hypertensive drug, such as angiotensin II receptor blocker, lipid lowering medication and aspirin (see Additional file [1](#S1){ref-type="supplementary-material"}).

The following information was obtained form the participant questionnaires: age at time of recruitment, gender, level of school education, marital status, occupational status, smoking history and alcohol consumption as well as number of appointments with the GP. Information on participants' self-estimated adherence to all prescribed medications was obtained by the 4-item self-report Morisky medication adherence questionnaire developed \[[@B12]\]. The sum score was calculated ranging from 0 (full adherence) to 4 (poor adherence). Patients were grouped as having a good (zero points), moderate (1 to 2 points) or poor adherence (3 to 4 points). The general health status was evaluated by the first question of the short-form-12 (SF-12) questionnaire \[[@B13]\].

Classification of glycemic control level was based on baseline HbA~1c~, defining ≤ 6.4% as good, 6.5% - 7.4% as moderate and ≥7.5% as poor \[[@B14]\].

Statistical analysis
--------------------

When information from the GPs' was not available (only 3.8% of the participants), information from the participants' questionnaires was used to minimize missing values, since we found very good agreement of both sources for participants for whom the information of both questionnaires was available (kappa coefficients for medications: \>0.90 and for comorbidities: \>0.80).

Descriptive statistics included 2-tailed t-tests for means and χ²-tests for proportions comparing differences between men and women. Analyzed covariates were socio-demographic characteristics, glycemic control, smoking status, alcohol consumption, diabetes duration, participation in a DMP-DM and comorbidities. Analyses on prescribed diabetes medication were stratified for gender and differentiated between the presence and absence CHD. Analyses on prescribed CHD medication were stratified for gender and restricted to participants with prevalent CHD. Logistic regression was employed to estimate unadjusted and adjusted odds ratios (ORs) and corresponding 95% confidence intervals (95%-CIs) for describing the association between gender and use of diabetes or CHD medication. In order to adjust for the main independent determinants, variables for multivariate logistic regression models were selected by backward selection separately for each medication group (diabetes and CHD medications). Variables with a p-value \< 0.1 were kept in the model to limit potential confounding. Statistical testing was two-sided, an alpha level of 5% was applied, and SAS 9.2 (SAS Institute, Cary, N.C., USA) was used throughout.

Results
=======

Overall, 624 men (54.4%) and 522 women (45.6%) participated in this study (Table [1](#T1){ref-type="table"}). On average, men were younger than women. Gender-specific differences also were found for other socio-demographic factors: women had a lower educational level, were more often singles and less often still employed. Smoking and alcohol consumption was far more prevalent in men than in women. Tentatively, more men than women showed a HbA~1c~ ≥ 7.5%. Men had significantly lower mean HDL levels than women. No gender differences were found for mean systolic or diastolic blood pressure. The number of GP appointments did not differ significantly between women and men. Self-reported medication adherence and self-rated general health status were similar between women and men. Men had significantly more often physician-diagnosed CVD and diabetes-related comorbidities, including CHD, intermittent claudication, stroke and diabetic nephropathy, whereas women had significantly more often a diagnosed depression.

###### 

Description of the study population

                                                         **Men**        **Women**      **p-value**               
  ------------------------------------------------------ -------------- -------------- -------------- ---------- --------------
  **Age in years (mean, SD\*)**                          67.2 (10.1)    69.7 (10.5)                              
  **Age in years**                                                                                                
   ≤59                                                   **137**        **22.0**       **84**         **16.1**    
   60 - 69                                               **193**        **30.9**       **129**        **24.7**    
   70 - 79                                               **239**        **38.3**       **231**        **44.3**    
   ≥80                                                   **55**         **8.8**        **78**         **14.9**   **0.0001**
  **Years of school education**                                                                                   
   ≤9                                                    **433**        **70.9**       **395**        **76.9**    
   10 - 12                                               **104**        **17.0**       **94**         **18.2**    
   ≥13                                                   **74**         **12.1**       **25**         **4.9**    **0.0001**
  **Marital status**                                                                                              
   Single/ widowed/ divorced                             **112**        **18.1**       **209**        **40.2**    
   Married                                               **508**        **81.9**       **311**        **59.8**   **\<0.0001**
  **Occupational status**                                                                                         
   Employed                                              **158**        **26.5**       **78**         **15.7**    
   Retired                                               **403**        **67.5**       **318**        **63.9**    
   Housewife                                             **0**          **0**          **80**         **16.1**    
   Other                                                 **36**         **6.0**        **22**         **4.4**    **\<0.0001**
  **Smoking history**                                                                                             
   Never                                                 **174**        **28.0**       **375**        **72.0**    
   Ex-smoker                                             **355**        **57.2**       **100**        **19.2**    
   Current smoker                                        **92**         **14.8**       **46**         **8.8**    **\<0.0001**
  **Alcohol consumption**                                                                                         
   Abstainer                                             **139**        **22.3**       **283**        **54.2**   **\<0.0001**
  **Body mass index (kg/m²)**                                                                                     
   \<25                                                  76             12.2           78             14.9        
   25 - \<30                                             255            40.9           187            35.8        
   30 - \<35                                             194            31.1           161            30.8        
   ≥35                                                   98             15.8           96             18.4       0.19
  **Glycemic control by HbA**~**1c**~                                                                             
   Good (≤6.4%)                                          241            38.6           213            41.1        
   Moderate (6.5 - 7.4%)                                 239            38.3           212            40.9        
   Poor (≥7.5%)                                          144            23.1           93             18.0       0.10
  **Mean HbA**~**1c**~**(SD) in**%                       6.9 (1.1)      6.8 (1.0)      0.14                      
  **Mean HDL (SD) in mg/dl**                             47.7 (14.3)    57.3 (17.2)    **\<0.0001**              
  **Mean systolic BP (SD) in mmHg**                      137.8 (18.1)   136.8 (19.0)   0.41                      
  **Mean diastolic BP (SD) in mmHg**                     79.4 (10.2)    79.6 (10.5)    0.68                      
  **Physician reported time since diabetes diagnosis**                                                           
   ≤5 years                                              241            38.6           213            40.8        
   6 -- 10 years                                         185            29.7           146            28.0        
   11 -- 15 years                                        104            16.7           81             15.5        
   ≥16 years                                             94             15.1           82             15.7       0.82
  **Appointments with GPs (last 3 months)**                                                                       
   ≤1                                                    260            41.7           197            37.9        
   2 -- 3                                                245            39.3           216            41.5        
   ≥4                                                    119            19.1           107            20.6       0.43
  **Participation in a DMP-DM**                          471            79.4           398            81.7       0.34
  **Medication adherence**                                                                                        
   Good                                                  455            75.6           385            77.0        
   Moderate                                              132            21.9           102            20.4        
   Poor                                                  15             2.5            13             2.6        0.83
  **General health status (self-rated)**                                                                          
   Excellent or very good                                62             10.0           40             7.7         
   Good                                                  366            58.7           291            55.8        
   Fair                                                  174            27.9           172            32.9        
   Poor                                                  21             3.4            19             3.6        0.21
  **Physician diagnosed comorbidities**                                                                           
   Hypertension                                          488            78.3           407            78.1       0.93
   Hypercholesterolemia                                  350            56.2           300            57.8       0.58
   Coronary heart disease                                **147**        **23.6**       **67**         **12.8**   **\<0.0001**
   Heart failure                                         75             12.0           64             12.3       0.89
   Intermittent claudication                             **96**         **15.4**       **36**         **6.9**    **\<0.0001**
   Stroke                                                **47**         **7.5**        **22**         **4.2**    **0.02**
   Nephropathy                                           **76**         **12.2**       **45**         **8.6**    **0.05**
   Retinopathy                                           51             8.2            35             6.7        0.35
   Neuropathy                                            144            23.1           104            20.0       0.20
   Depression                                            **67**         **10.7**       **97**         **18.6**   **0.0002**
   Cancer                                                63             10.1           49             9.4        0.70

\*SD = standard deviation; HbA~1c~ = glycated haemoglobin A1c; GP = general practitioner;

DMP-DM = disease management program for treatment of patients with type 2 diabetes.

Missing values: education: 21, marital status: 6, occupational status: 51, smoking: 4, BMI: 1, HbA1c: 4, HDL: 270, systolic and diastolic BP: 70, appointments with GPs: 2, DMP-DM: 66, adherence: 44, health status: 1, hypertension: 2, hypercholesterolemia: 4, CHD: 2, heart failure: 1, intermittent claudication: 1, stroke: 2, nephropathy: 1, retinopathy: 1, depression: 1, cancer: 1

Significant results (p \< 0.05) by χ² test are printed bold.

Characteristics of diabetes medication stratified for gender and prevalent coronary heart disease are described in Table [2](#T2){ref-type="table"}. Significantly more men than women took at least one diabetes medication (men: 77.7% vs. women: 69.6%, p = 0.01). The most frequently prescribed diabetes drugs in men and women were biguanides, sulfonylureas and insulins. The prescription of more expensive diabetes drugs, such as GLP-I analogues, DPP-4 inhibitors and oral combination drugs, was rather low among our study participants. Statistically significant gender-specific differences were evident for thiazolidinediones (p = 0.04) and oral combination drugs (p = 0.02). Overall, prescription of insulin (insulin or insulin analogue) was almost equally frequent among men and women, but was far more common among patients with CHD than without. The number of diabetes medications was statistically significantly increasing with level of glycemic control in men and women (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

###### 

Diabetes medication by gender and prevalent coronary heart disease

  **Medication of interest**                                                  **With coronary heart disease**   **Without coronary heart disease**                                                                                  
  --------------------------------------------------------------- ----------- --------------------------------- ------------------------------------ ----------- ----------- ----------- ---- ------ --------- ---------- --------- ----------
  **Number of diabetes medication (mean, STD\*)**                 1.3 (1.1)   1.3 (1.2)                         1.5 (1.3)                            1.4 (1.1)   1.3 (1.1)   1.2 (1.2)                                              
  **Number of diabetes medication**                                                                                                                                                                                                 
  0                                                               **138**     **22.3**                          **158**                              **30.4**    27          18.5        15   22.7   **111**   **23.5**   **143**   **31.6**
  1                                                               **245**     **39.6**                          **175**                              **33.7**    50          34.3        22   33.3   **195**   **41.2**   **153**   **33.8**
  2                                                               **159**     **25.7**                          **113**                              **21.8**    46          31.5        17   25.8   **113**   **23.9**   **96**    **21.2**
  3 and more                                                      **77**      **12.4**                          **73**                               **14.1**    23          15.7        12   18.2   **54**    **11.4**   **61**    **13.5**
  **Biguanide**                                                   343         55.0                              273                                  52.3        70          47.6        35   52.2   273       57.2       238       52.3
  **Sulfonylurea**                                                132         21.2                              92                                   17.6        32          21.8        14   20.9   100       21.0       78        17.1
  **Alpha-glucosidase inhibitor**                                 14          2.2                               13                                   2.5         5           3.4         1    1.5    9         1.9        12        2.6
  **Thiazolidinedione**                                           **39**      **6.3**                           **19**                               **3.6**     11          7.5         3    4.5    28        5.9        16        3.5
  **Glinide**                                                     21          3.4                               13                                   2.5         6           4.1         1    1.5    15        3.1        12        2.6
  **Glucagon-like peptide-I analogue (GLP-I) exenatide**          6           1.0                               5                                    1.0         4           2.7         0    0      2         0.4        5         1.1
  **Dipeptidyl peptidase-4 (DPP-4) inhibitor**                    20          3.2                               28                                   5.4         7           3.3         4    6.0    17        3.6        24        5.3
  **Oral combination drug**                                       **26**      **4.2**                           **9**                                **1.7**     6           4.1         1    1.5    **20**    **4.2**    **8**     **1.8**
  **Insulin treatment**                                           123         19.8                              107                                  20.5        43          29.7        20   29.8   80        16.8       87        19.1
  **Short acting insulin**                                        47          7.5                               40                                   7.7         16          10.9        7    10.4   31        6.5        33        7.3
  **Intermediate acting (basal insulin)**                         53          8.5                               56                                   10.7        19          12.9        10   14.9   34        7.1        46        10.1
  **Human insulin combination (short and intermediate acting)**   22          3.5                               14                                   2.7         8           5.4         4    6.0    14        2.9        10        2.2
  **Insulin analogue**                                            58          9.3                               43                                   8.2         22          15.0        8    11.9   36        7.5        35        7.7

\*SD = standard deviation. Number may not always add up to total because of missing values for some items.

Significant results (p \< 0.05) by χ²-test are printed bold.

![Mean number (± standard error) of diabetes medication by glycemic control.](1475-2840-11-88-1){#F1}

![Mean number (± standard error) of diabetes medication by diabetes duration.](1475-2840-11-88-2){#F2}

Table [3](#T3){ref-type="table"} shows the prevalence of CHD medication stratified by gender. Statistically significant gender-specific differences were found for ACE inhibitors (p = 0.003), calcium channel blockers (p = 0.01) and aspirin (p = 0.002). In the group of CHD patients, statistically significant gender-specific differences were only evident for ACE inhibitors (p = 0.02) and calcium channel blockers (p = 0.004).

###### 

Coronary heart disease medication by gender and prevalent coronary heart disease

  **Medication of interest**                            **All**   **With coronary heart disease**                                                      
  ----------------------------------------------------- --------- --------------------------------- --------- ---------- --------- ---------- -------- ----------
  **Antihypertensive drug**                             507       81.3                              412       78.9       144       98.0       63       94.0
   ** Angiotensin-converting enzyme (ACE) inhibitor**   **431**   **69.1**                          **316**   **60.5**   **120**   **81.6**   **45**   **67.2**
   ** Diuretic**                                        186       29.9                              176       33.7       70        47.9       34       50.7
   ** Beta-blocker**                                    267       42.8                              228       43.7       112       76.2       48       71.6
   ** Calcium channel blocker**                         **168**   **26.9**                          **106**   **20.3**   **50**    **34.0**   **10**   **14.9**
  **Lipid lowering drug**                               277       44.4                              216       41.4       110       74.8       45       67.2
  **Aspirin**                                           **213**   **34.1**                          **133**   **25.5**   102       69.4       45       67.2

Number may not always add up to total because of missing values for some items. Significant results (p \< 0.05) by χ²-test are printed bold.

The results of logistic regression analyses regarding the association between gender and diabetes and CHD medications with significant gender differences (p \< 0.05) are described in Table [4](#T4){ref-type="table"}. Men had 53% increased odds to receive any antidiabetic drug compared to women (95%-CI: 1.17 -- 1.99, no table). Men compared to women had 1.8 and 2.5 higher odds to receive thiazolidinediones and oral combination drugs. After stratification for CHD, no significant gender-specific difference in diabetes medication was seen. After full model adjustment men had still 44% and 42% increased odds to receive ACE inhibitors and calcium channel blockers. A positive association between male gender and antithrombotic therapy with aspirin was also observed. In participants with CHD, gender-specific prescription differences of ACE inhibitors and calcium channel blockers were particularly strong. Significant gender differences in ACE inhibitors in CHD patients with diabetes sustained after adjusting for age, Hba~1c~, appointements with GP, medication adherence and comorbidities that are indications for renin-angiotensin system (RAS) blockade. Overall, all logistic regression models showed a very good model fit by Hosmer-Lemeshow test.

###### 

Results of diabetes and coronary heart disease medication: Odds ratios (95% confidence intervals) for men compared to women (reference)

                                                                              **Total**          **With coronary heart disease**   **Without coronary heart disease**
  --------------------------------------------- --------------------- ------------------------- --------------------------------- ------------------------------------
  **Diabetes Medication**                                                                                                         
  **Thiazolidinedione**                         **Crude**                1.77 (1.01 - 3.09)            1.73 (0.47 - 1.58)                  1.71 (0.91 - 3.21)
                                                **Adjusted**^**a**^      1.75 (0.99 - 3.08)            1.58 (0.41 - 6.07)                  1.68 (0.89 - 3.17)
                                                **Adjusted**^**b**^     1.42 (0.79 - 2.57)^1^         0.94 (0.28 - 3.17)^2^              1.52 (0.81 - 2.85)^3^
  **Oral combination drug**                     **Crude**                2.48 (1.51 - 5.34)            2.81 (0.33 - 23.79)                 2.45 (1.07 - 5.61)
                                                **Adjusted**^**a**^      1.97 (0.94 - 4.13)            1.82 (0.21 - 15.96)                 1.91 (0.82 - 4.45)
                                                **Adjusted**^**b**^     2.06 (0.98 - 4.31)^4^         1.93 (0.38 - 9.78)^5^              1.87 (0.84 - 4.13)^6^
  **Coronary Heart Disease Medication**                                                                                           
  **Angiotensin-converting enzyme inhibitor**   **Crude**                1.46 (1.14 -- 1.86)           2.17 (1.12 -- 4.20)                          
                                                **Adjusted**^**a**^      1.52 (1.18 -- 1.95)           2.18 (1.09 -- 4.35)                          
                                                **Adjusted**^**c**^    1.44 (1.11 -- 1.88)^7^                  \-                                   
                                                **Adjusted**^**d**^              \-                  2.61 (1.26 -- 5.42)^8^                         
  **Calcium channel blocker**                   **Crude**                1.45 (1.10 -- 1.91)           2.94 (1.38 -- 6.24)                          
                                                **Adjusted**^**a**^      1.55 (1.17 -- 2.06)           3.53 (1.58 -- 7.89)                          
                                                **Adjusted**^**c**^    1.42 (1.05 -- 1.91)^9^                  \-                                   
                                                **Adjusted**^**d**^                                  3.64 (1.55 -- 8.52)^10^                        
  **Aspirin**                                   **Crude**                1.52 (1.17 -- 1.96)           1.10 (0.58 -- 2.08)                          
                                                **Adjusted**^**a**^      1.80 (1.38 -- 2.36)           0.96 (0.49 -- 1.87)                          
                                                **Adjusted**^**e**^    1.36 (1.01 -- 1.84)^11^                 \-                                   
                                                **Adjusted**^**f**^              \-                  1.12 (0.57 -- 2.21)^12^                        

Adjusted for: ^a^age and HbA~1c~ level, ^b^age, HbA~1c~ level, physician reported diabetes duration, appointments with the GP, marital status, diabetic nephropathy, depression, ^c^age, HbA~1c~ level, appointments with the GP, medication adherence, coronary heart disease, stroke, intermittent claudication, diabetic nephropathy and depression, ^d^age, HbA~1c~ level, appointments with the GP, medication adherence, stroke, intermittent claudication, diabetic nephropathy and depression, ^e^age, HbA~1c~ level, appointments with the GP, medication adherence, coronary heart disease, stroke, diabetic nephropathy and depression, ^f^age, HbA~1c~ level, appointments with the GP, medication adherence, stroke, diabetic nephropathy and depression.

Goodness of fit: ^1^p = 0.74; ^2^p = 0.87; ^3^p = 0.33; ^4^p = 0.66; ^5^p = 0.85 ^6^p = 0.66; ^7^p = 0.83; ^8^p = 0.46; ^9^p = 0.93; ^10^p = 0.70; ^11^p = 0.13; ^12^p = 0.76.

Discussion
==========

Our results demonstrate that men with diabetes were significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers for CHD than women. Gender-specific differences could also be observed for aspirin use for the overall study sample, but not for the CHD subsample. Taken together, these patterns suggest that diabetic men might be more thoroughly treated than women, especially in terms of CHD medication. Furthermore, the number of diabetes medication was significantly increasing with the level of glycemic control and diabetes duration in men and women with diabetes.

Our finding of gender-specific, also not statistically significant differences in the prescription of diabetes medication such as thiazolidinediones is in accordance with the results of a German cross-sectional study \[[@B15]\]: Lehnert et al. analyzed data on 6,786 people with diabetes in primary care and found a slightly higher prescription rate of thiazolidinediones in men (4.4%) than in women (3.6%) above the age of 60 years. Apart from the different time frames of the studies (Lehnert et al.: 2001; our study: 2008--2010), differences in prescription rates might be mainly explained by disparities in diabetes duration (Lehnert et al.: 4.5 (±1.2 years) vs. our study: 8.8 (±7.1 years)) which is one of the main determinants of treatment choice. Reasons for the higher prescription of thiazolidinediones in men than in women are unclear. Studies have suggested that thiazolidinediones have beneficial effects on inflammatory and atherogenic parameters, blood pressure and microalbuminuria \[[@B16]\] and that thiazolidinediones doubles the risk of fractures among women, but not among men with diabetes \[[@B17]\]. Due to severe side effects the most frequently prescribed thiazolidinediones, namely Rosiglitazone and Pioglitazone, can no longer be prescribed for diabetes treatment in Germany since April 2011 \[[@B18]\], and Rosiglitazone was recommended for suspension by the European Medicines Agency (EMA) in September 2010 \[[@B19]\].

The higher prescription rate of oral combination drugs in men compared to women with T2DM might be explained by the higher number of comorbidities and burden of disease in participating men compared to women and the attempt of the general practitioners to reduce the overall number of medication especially for men.

Our findings regarding CHD medication are in line with previous research: The results of the Euro Heart Survey on Heart Failure including 8,914 patients with heart failure showed that women got less ACE inhibitors and beta-blockers than men \[[@B20]\]. A German cross-sectional study on 1,857 consecutive patients with heart failure likewise showed a difference in the prescription of ACE inhibitors and dosage of beta-blockers, and revealed a less evidence-based treatment in women than in men \[[@B21]\]. For patients with diabetes mellitus, a Swedish study including 229 primary care centres revealed - similar to our study - that men were more often prescribed ACE inhibitors than women and that only one third of the patients below 75 years was on lipid-lowering drug therapy \[[@B22]\]. The higher prescription rate of ACE inhibitors among men can potentially be explained not only by the higher CVD comorbidity, but also by the higher prevalence of nephropathy in men than in women and the protective effect of ACE inhibitors towards progression of nephropathy \[[@B23]\]. Brannström et al \[[@B24]\] investigated gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in a cohort of elderly people aged 85 years or older. Women received significantly more drugs, more diuretics, more nitrates. In contrast to our study, no differences were found for insulin therapy, Aspirin and ACE inhibitors, but ACE inhibitor prescription rates were considerably lower in this study compared to ours. For patients with coronary events or revascularisation the EUROASPIRE III study found higher ACE-inhibitors prescription rates for men than for women. Women receive more diuretics, insulin and oral antidiabetic agents \[[@B25]\]. Lipid lowering treatment is generally recommended for all people with T2DM with a high risk for macroangiopathic complications or with CHD \[[@B26]\]. The underuse of lipid lowering drugs together with a lack of antithrombotic drugs might point to a suboptimal quality of health care, because both are crucial for the reduction of cardiovascular comorbidity and all-cause mortality in people with diabetes \[[@B27]-[@B29]\]. A large Danish primary care study \[[@B30]\] on patients screened for diabetes with a high risk for CVD and a large US retrospective study \[[@B31]\] on people with diabetes found that less women than men received an adequate lipid-lowering treatment. In our study which was conducted between 2008 and 2010, already 43% of the patients with diabetes received lipid lowering drugs, but with no differences between men and women.

In summary, as various studies \[[@B32],[@B33]\] and a recently published review \[[@B34]\] point out, gender differences regarding diabetes mellitus are present for all steps in the glucometabolic pathway starting with differences in patho-physiological disturbances, the risk factor distribution, incidence and prevalence of complications, and finally diagnostic techniques and therapy. Franconi et al conclude, that a gender specific approach for all aspects of patient care is much needed to improve overall perspective of patients with diabetes mellitus \[[@B34]\].

Our study results are limited by the cross-sectional study design, i.e. causality cannot be derived and no conclusion on trends in treatment can be drawn. In particular, our study did not allow identifying with certainty the potential reasons underlying gender differences in medication. The relatively small numbers in each medication group limited the power to detect differences of small and moderate size. Although we aimed for the inclusion of all people with T2DM in a large number of practices, selection effects of participating GPs and regional variation in treatment might limit generalizability. Furthermore, the insurance status was not recorded at baseline. We could not perform a detailed monitoring of completeness of recruitment of diabetes patients in the practices.

Conclusions
===========

Men with diabetes were significantly more likely to receive oral combination drugs, ACE inhibitors and calcium channel blockers in the presence of coronary heart disease. These patterns suggest that diabetic men might be more thoroughly treated than women, especially in terms of CHD medication. We hope that our results will contribute to and stimulate the discussion on gender-specific disparities in diabetes healthcare.
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